Capsule Endoscopy Market Size, Share, Industry, Forecast and outlook (2024-2031)

Capsule Endoscopy Market is Segmented By Product (Capsule Endoscopes, Small Bowel, Esophageal, Colon, Systems, Others), By Application (Crohn’s Disease, OGIB (obscure GI tract bleeding), Small Intestine Tumor, Others), By End-User (Hospitals, Ambulatory surgery centers, Other), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030.

The Capsule Endoscopy Market is expected to reach growing at a CAGR of 8.7% during the forecast period (2023-2030).

Capsule endoscopy is a procedure in which a large vitamin pill and a small capsule are swallowed. A tiny wireless camera inside the capsule takes pictures as it travels through the small intestine. Images are transmitted to a recording device worn around the waist on a belt.

Capsule Endoscopy Market Scope

Market Dynamics

The factors influencing the global capsule endoscopy market are the increasing technological advancements in endoscopy procedures.

The increasing technological advancements in endoscopy procedures is expected to drive the global capsule endoscopy market in the forecast period

The fiberoptic endoscope (fiberscope) era has given way to the video scope and, more recently, the capsule endoscope. Video endoscopy will continue to be the most common type of endoscopy for the next 5-10 years, but diagnostic procedures such as colonoscopy are expected to be performed by capsule endoscopy. Because of its convenience and noninvasiveness, capsule endoscopy has revolutionized the management of small-bowel diseases. Capsule endoscopy is a standard procedure to diagnose obscure gastrointestinal bleeding, Crohn's disease, small-bowel tumours, and polyposis syndrome.

For instance, on November 15, 2021, PillCam Small Bowel 3 system for remote endoscopy procedures. The PillCam SB3 @HOME program combines Medtronic's PillCam technology with Amazon logistics, aiming to provide patients with timely and accurate results from the comfort of their own homes. PillCam SB3 @HOME is a telehealth option for direct visualization and monitoring of the small bowel, which can help detect lesions that are not detected by upper and lower endoscopy and may: indicate Crohn's disease, locate obscure bleeding, or identify sources of iron deficiency anemia (IDA).

Limitations associated with the use of capsule endoscopy is expected to hamper the market growth

While the capsule is the best way to see the inside of the small intestine, it has many inherent limitations and problems, and the most important is that it does not allow for therapy. Because of the capsule's rapid transit and blurry, unintelligible photographs, abnormalities in some areas of the intestine are missed. Retained stool or food debris can also blur the images. The primary risk of capsule endoscopy is device retention in the small bowel. The risk is very low, about one to two percent, in patients who have the test to evaluate for bleeding. The risk may rise to four to five percent in Crohn's disease patients. The majority of cases of capsule retention resolve spontaneously after a brief delay in the passage of the capsule, and the majority of patients have no symptoms at all. As a result, proper bowel preparation is essential prior to the capsule endoscopy. Reviewing tens of thousands of photographs takes a significant amount of time for the conscientious physician.

COVID-19 Impact Analysis

In the context of the COVID-19 pandemic, capsule endoscopy (CE) has distinct advantages over other gastrointestinal endoscopy modalities such as single-use with low risk of cross-infection, excellent tolerance with low risk of aerosol generation, minimal medical staff requirement (one staff member-only), and separation of examination and reading/reporting. For instance, the recently introduced non-contact magnetically controlled capsule endoscopy (MCE) system allows for infection-free upper gastrointestinal examination (especially the stomach) under remote control, ensuring the safety of medical staff while providing high-quality endoscopy service patients.

Hence, the advantages capsule endoscopy provided during COVID-19 are expected to drive market growth.

Segmentation Analysis

Based on product, the capsule endoscopes segment is expected to dominate the market

Capsule endoscopy involves using a swallowed video capsule to photograph the inside of the gastrointestinal tract. The main applications are examinations of the oesophagus, stomach, colon, and small and large intestines. Traditional endoscopes are inserted transorally or transanally, which can be uncomfortable for the patient, particularly because the small intestine can be difficult to reach during a traditional endoscopic examination. Many companies are manufacturing capsule endoscopes for the examination of different parts. The endoscope's design also increases the possibility of damage or lesions in the organs being examined. This digestible camera is the primary medical device used in a capsule endoscope procedure. A capsule endoscope is a small wireless device that can image the gastrointestinal tract. The receiver carried by the patient collects the data transmitted from the pill cam.

For instance, on September 29th, 202o, the FDA approved the use of CapsoVision's CapsoCam Plus, a small bowel capsule endoscope at home during the pandemic.

Geographical Analysis

North America region is expected to hold the largest market share in the global capsule endoscopy market

The growing preference for minimally invasive screening procedures and the adoption of technologically advanced products and systems. Furthermore, improved healthcare infrastructure and rising awareness about the early detection of diseases such as gastrointestinal disorders, Ambulatory surgery centers, and other chronic conditions are driving market growth in the region.

For instance, 75 million endoscopies are performed in the United States every year, with 51.5 million, or 68 percent, being gastrointestinal endoscopies. Furthermore, on November 15th, 2021, the US Food and Drug Administration (FDA) approved the PillCam Small Bowel 3 system for remote endoscopy procedures.

Competitive Landscape

The global capsule endoscopy market is highly competitive with FDA approvals, mergers, and product launches. Some of the key players are Given Imaging (Medtronic Plc), Olympus Corporation, IntroMedic, Co. Ltd., Chongqing Jinshan Science & Technology (Group) Co., Ltd., CapsoVision, RF System lab, Check-Cap, Advin Health Care

Medtronic Plc

Overview: Medtronic plc is a medical device company. Medtronic's operational and executive headquarters are in Minneapolis, Minnesota, in the United States. The company was founded in 1949. The Company operates in four segments: Cardiac and Vascular Group, Restorative Therapies Group, Minimally Invasive Technologies Group, and Diabetes Group.

Product Portfolio: The PillCam capsule endoscopy platform produces clear images of the oesophagus, stomach, small bowel, and colon utilizing innovative visualization technology. This non-invasive platform enables doctors to detect GI abnormalities, track disease activity, and evaluate treatment efficacy.

Key Development: On November 15th, 2021, the US Food and Drug Administration (FDA) approved the PillCam Small Bowel 3 system for remote endoscopy procedures. The PillCam SB3 @HOME program combines Medtronic's PillCam technology with Amazon logistics, aiming to provide patients with timely and accurate results from the comfort of their own homes.